603590 Beijing Konruns Pharmaceutical
- 21.42
- -0.49-2.24%
Beijing Konruns Pharmaceutical News
Kangchen Pharmaceutical Announces Results of the 2023 Restricted Stock Incentive Plan Reservation Grant
Kangchen Pharmaceutical\'s progress announcement on changes in the nature of shares and the reservation grant of restricted stock incentive plans
Kangchen Pharmaceutical 2024 Semi-Annual Report
Announcement of Resolutions of the 9th Meeting of the Fourth Board of Supervisors of Kangchen Pharmaceutical
Summary of Kangchen Pharmaceutical\'s 2024 Semi-Annual Report
Kangchen Pharmaceutical\'s announcement on the appointment of Chief Financial Officer
Kangchen Pharmaceutical\'s announcement on renewing the employment of an accounting firm
Kangchen Pharmaceutical\'s special report on the storage and actual use of funds raised in the 2024 semi-year
Beijing Kangchen Pharmaceutical Co., Ltd. Accountant Service Selection and Employment System
Announcement of Resolutions of the 11th Meeting of the Fourth Board of Directors of Kangchen Pharmaceutical
Announcement on using part of the idle raised funds for cash management redemption by Beijing Konruns Pharmaceutical
Announcement of Resignation of Senior Management Personnel from Beijing Konruns Pharmaceutical
Beijing Konruns Pharmaceutical: Announcement from Beijing Konruns Pharmaceutical on traditional Chinese medicine innovative drug ZY5301 clinical research results being featured in the sub-journal of JAMA.
Announcement from Beijing Konruns Pharmaceutical on traditional Chinese medicine innovative drug ZY5301 clinical research results being featured in the sub-journal of JAMA.
Beijing Konruns Pharmaceutical's Supervisory Board's statement on the publicity and verification of the reserved list of incentive objects for the restricted stock incentive plan for the company in 2023.
Announcement on the Change of Continuous Supervision and Sponsorship Representative of Beijing Konruns Pharmaceutical
Beijing Konruns Pharmaceutical's announcement about the first release of the restricted stock incentive plan in 2023 and the achievement of the first unlocking condition
Announcement of Resolution of the Tenth Meeting of the Fourth Board of Directors of Beijing Konruns Pharmaceutical.
Announcement of Konruns Pharmaceutical regarding repurchasing restricted stocks that have been granted but have not yet been released from restriction, and adjusting buyback price.
The supervisory board's verification opinion on matters related to the 2023 restricted stock incentive plan.
Analysis
Price Target
No Data
